Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer.
The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data.
The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about.
To put this regulatory update in context, consider reviewing other healthcare stocks leveraging AI-powered approaches across drug development and treatment decisions through 37 healthcare AI stocks.
NasdaqGS:EXEL Earnings & Revenue Growth as at Sep 2026
Exelixis focuses on oncology medicines for difficult-to-treat cancers, so regulators scrutinize its new therapies closely given the patient groups involved. With a market cap of about $14.5b, the business sits among larger US biotechs working on targeted cancer treatments and immunotherapy combinations.
How this FDA delay feeds into the Exelixis investment story
The Exelixis Narrative rests on turning a cabozantinib heavy franchise into a broader oncology portfolio, with zanzalintinib seen as a key second pillar in colorectal cancer. This FDA extension does not alter that premise, but it does test how resilient that story is when regulatory timelines shift.
“Positive top-line results from pivotal trials (e.g., STELLAR-303 for zanzalintinib in colorectal cancer) and an advancing late-stage pipeline provide significant potential for new product approvals and label expansions…”
See how the full story points towards a $53.00 fair value for Exelixis.
This update slightly strengthens the diversification angle in Exelixis’ Narrative because the FDA is engaging with a larger, more mature dataset for zanzalintinib. A three month delay is unhelpful for timing, but it points to Exelixis trying to position the regimen as a durable metastatic colorectal cancer option in a field that includes players such as Roche and Merck.
The unresolved issue is whether zanzalintinib can realistically shoulder enough future demand to offset Exelixis’ reliance on cabozantinib once key protections expire. Analysts have already flagged patent exposure and pipeline uncertainty as pressure points, and this extended review keeps the question of eventual colorectal cancer market share wide open.
News like this only really makes sense when viewed against where Exelixis says it is heading over the next decade, which is exactly what a clear Narrative is designed to lay out.
Add Exelixis to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EXEL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com